628 related articles for article (PubMed ID: 19229819)
21. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
[TBL] [Abstract][Full Text] [Related]
22. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Akiba T; Hirakata H; Kinugasa E; Tominaga Y; Fukagawa M; Yokoyama K; Zhang W; Linde PG; Suzuki M
Ther Apher Dial; 2015 Jun; 19(3):225-34. PubMed ID: 25363733
[TBL] [Abstract][Full Text] [Related]
23. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Llach F; Yudd M
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
[TBL] [Abstract][Full Text] [Related]
24. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease.
Hervás Sánchez JG; Prados Garrido MD; Polo Moyano A; Cerezo Morales S
Nefrologia; 2011; 31(6):697-706. PubMed ID: 22130286
[TBL] [Abstract][Full Text] [Related]
26. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
27. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
[TBL] [Abstract][Full Text] [Related]
28. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
29. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
Abboud H; Coyne D; Smolenski O; Anger M; Lunde N; Qiu P; Hippensteel R; Pradhan RS; Palaparthy RV; Kavanaugh A; Melnick JZ; Williams LA; Batlle D
Am J Nephrol; 2006; 26(1):105-14. PubMed ID: 16543714
[TBL] [Abstract][Full Text] [Related]
30. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
Coyne DW; Goldberg S; Faber M; Ghossein C; Sprague SM
Clin J Am Soc Nephrol; 2014 Sep; 9(9):1620-6. PubMed ID: 24970869
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.
Lund RJ; Andress DL; Amdahl M; Williams LA; Heaney RP
Am J Nephrol; 2010; 31(2):165-70. PubMed ID: 20016142
[TBL] [Abstract][Full Text] [Related]
32. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
Kumar N; Lindberg J; David K; Morris J; Menoyo J
Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
35. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
[TBL] [Abstract][Full Text] [Related]
36. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
37. Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism.
Ong LM; Narayanan P; Goh HK; Manocha AB; Ghazali A; Omar M; Mohamad S; Goh BL; Shah S; Seman MR; Vaithilingam I; Ghazalli R; Rahmat K; Shaariah W; Ching CH;
Nephrology (Carlton); 2013 Mar; 18(3):194-200. PubMed ID: 23311404
[TBL] [Abstract][Full Text] [Related]
38. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.
Zisman AL; Ghantous W; Schinleber P; Roberts L; Sprague SM
Am J Nephrol; 2005; 25(6):591-5. PubMed ID: 16282676
[TBL] [Abstract][Full Text] [Related]
40. Iatrogenic hypercalcemia in hemodialysis patients.
Muhammedi MA; Piraino B; Rault R; Johnston JR; Puschett JB
Clin Nephrol; 1991 Nov; 36(5):258-61. PubMed ID: 1752077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
